59
1 譚延輝博士 簡歷 ([email protected]) l 現任高雄醫學大學 藥學系 副教授 l 學歷 l 1989~93 美國亞歷桑納大學 藥學行政與行為科學 哲學博士 l 1985~86 美國愛荷華大學 臨床/醫院藥學 碩士 l 1976~80 國防醫學院 藥學系 學士 l 專業經驗 l 2010~2016:執行長 藥事照護發展中心 藥師公會全聯會 l 2016~2019member of ACPE International Commission(藥學教育評鑑委員) l 2014~2016國際藥物經濟暨效果研究學會(ISPOR) 理事會理事,亞太區主席 l 2005~現在:世界藥學會(FIP),西太平洋藥事論壇(WPPF) 副主席 l 2003~現在:台灣藥物經濟暨效果研究學會: 理事長/常務理事/監事 l 2007~2009組長,醫藥科技評估組,財團法人醫藥品查驗中心 l 2007/ 5月: 系主任,台北醫學大學藥學院 藥學系 l 20052006部主任,台北市立聯合醫院藥劑部。負責十個院區 l 19932004副教授,國防醫學院 藥學系 人生使命: 1. 藥物經濟學有應用舞台 2. 藥師有直接照顧病人舞台

1985~86 1989~93 美國愛荷華大學 譚延輝博士 臨床 醫院藥學 碩 …

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

l
l l 1989~93 l 1985~86 / l 1976~80
l
l 2010~2016
l 2016~2019member of ACPE International Commission() l 2014~2016(ISPOR)
l 2005~(FIP)(WPPF)
l 2003~ //
l 2007~2009
l 2007/ 5
l 20052006
l 19932004
: 1. 2.

l
1.
2.
3.
2013(FIP) l Towards a Future Vision for Complex Patients _ Integrated Care in a Dynamic Continuum
l _ l
l Biological complexities () l Medically complex () – Pharmacologically complex ( 5) l Socioeconomic factors () l Cultural factors () l Geographical complexities () 4

Ø
Ø
Ø
X Nitrostat 0.6mg nitroglycerin 1# PRN
X Plavix 75mg clopidogrel 1# QD
X Imdur 60mg isosorbide 5- mononit 1# QD
X Dipyridamole 25mg "standard dipyridamole 1# TID
X Solantin 25mg dipyridamole 1# TID
X Inderal 10mg propranolol 1# TID
X Norvasc 5mg amlodipine 1# QD
X Co-diovan 80/12.5 valsartan 1# QD
X BPH, Doxaben XL 4mg doxazosin 1# HS

X Crestor 10mg Rosuvastatin 1# QD
X Arcoxia 60mg Etoricoxib 1# QD
X Bromarone100mg "H.C" Benzbromarone 1# QD
X Deflam-k F.C. Tablets 50mg Diclofenac potassium 1# TID
X Conicine tablets 0.5mg "H.H" Colchicine 1# TID
X Strocain 5mg Oxethazaine 1# TID
X Tigawet tablets

l 3
l 2 5 15 /
l 8
: Colchicine
l 105 Colchicine 0.5 mg QID 7 Strocaine 1 tab QID 7 101971022 colchicine QID1026 colchicine 0.5 mg QID 14 daysStrocaine 1 tab QID 14 Gascon 40 mg QID 5 Prochlorperazine 5 mg QID 5 Azulene 2 mg 1# QID 5 Loperamide (Imodium) 2 mg PRN
l 1027~31Imodium 111 26:30 colchicine QID116
l colchicine11 10
9
10
20156 3
l

11
(2010~2016)
2015 1(1021010309)90 2213
190 508 190 7
l
*** 2013~15170 8,000 ***
2010>200 →100

Ø 50%
:53.9±16.2 :44.8±18.2 - 17%
: 60.97±28.72 : 48.54±27.01 -20.4%

61,512±483 52,948±508 - 14% -$42,528,824
56,896±489 47,948±447 - 15.7%
-$71,924,024
-$63,255,767

14,377±16,961 14,024±69,969 -3%
: 13,993±21,136 : 12,483±19,147 -10.8%
  ( : )
Ø__1,000 ()

16
1. 2. _____ _____ 3. 4.
A1. 2 A2. 2 A3. 5 A4. 8+++
1. 65A1 B2 2. /A1 B2 3. A1 B2
B1. B2. B3. B4. () B5.
2013~2014 l/
l 2 l 2 l 5 l 8( + +)
l
Anticoagulation clinic Asthma-allergy clinic / Cardiac clinic Cardiovascular risk factor management clinic Diabetic nephropathy clinic Geriatrics clinic Heart failure clinic Human immunodeficiency virus (HIV) clinic Inflammatory bowel disease clinic Lipid clinic Medication management service Medication therapy management (cardiology) clinic Pediatric epilepsy ambulatory clinic Pain clinic Percutaneous coronary intervention clinic Peritoneal dialysis clinic Rheumatology monitoring clinic Smoking cessation clinic Transplant clinic

()→ ()
06/2016

1. 2. 3. 4. / ()
1.
2.

1. 2. 3. 4.
1
1VIS
broad narrow
Balance specialization with the risk of dis-continuity of care. Remember to treat the patient not the condition.
ü ü ü
ü ü ü ü ü
ü ü ü
Pharmacist-only certification 2012
Ambulatory Care Pharmacy () Board of Pharmacy Specialties
(BPS) Board Certified Ambulatory Care
Pharmacist (BCACS) NCCA*
Nutrition Support Pharmacy () Board of Pharmacy Specialties
(BPS) Board Certified Nutrition Support Pharmacist (BCNSP) NCCA*
Oncology Pharmacy () Board of Pharmacy Specialties
(BPS) Board Certified Oncology Pharmacist(BCOP) NCCA*
Psychiatric Pharmacy () Board of Pharmacy Specialties
(BPS) Board Certified Psychiatric Pharmacist(BCPP) NCCA*
Pharmacotherapy () Board of Pharmacy Specialties
(BPS) Board Certified Pharmacotherapy
Board Certified Pharmacotherapy Specialist (BCPS) with Added Qualifications in Cardiology
NCCA*
Board of Pharmacy Specialties (BPS)
Board Certified Pharmacotherapy Specialist (BCPS) with Added Qualifications in Infectious Diseases
NCCA*
23
Multidisciplinary Certifications - Available to pharmacists
Program Certification Body Credential Earned Certification Body Accredited By
Anticoagulation Care () National Certification Board for Anticoagulation
Providers (NCBAP) Certified Anticoagulation Care Provider (CACP)
Asthma Education () National Asthma Educator
Certification Board (NAECB) Certified Asthma Educator (AE-C)
Cardiovascular/Life Support American Heart Association Advanced Cardiovascular Life Support (ACLS)
American Heart Association Pediatric Advanced Life Support (PALS)
Clinical Pharmacology American Board of Clinical
Pharmacology (ABCP) Accredited in Applied Pharmacology (AP)
Diabetes Education () National Certification Board for Diabetes Educators
(NCBDE) Certified Diabetes Educator (CDE)
Diabetes Management - Advanced
Heath Information Technology Health IT Certification Certified Professional in Electronic Health Records (CPEHR)
Health IT Certification Certified Professional in Health Information Technology (CPHIT)
Health IT Certification Certified Professional in Health Information Exchange (CPHIE)
24
25
()
()
()
()
()
()
()
l
Robert J. Cipolle, Linda M. Strand, Peter C. Morley., Pharmaceutical care practice the clinician’s guide. 2nd ED. New York: McGraw Hill; 2004. 2010;102:S33-S38. 2010;102:S59-S69.
28
l
l

http://www.tpech.gov.tw/lp.asp?ctNode=13750&CtUnit=7952&BaseDSD=7&mp=109011
l l
33
Ø 34
Ø Ø( ) Ø
35

Ø
(1) (2) (3) (4) Ø () Ø ( ) Ø
36
37
1. (GPP) 1.1 (GDP) 2. 2.1
3.
4. 4.1 4.1.1
5.
5.1
5.4
5.5
2015 (I)
8.

9.
10. 10.1 10.2 10.3 10.4 10.5 10.6
11.
17. 18. 19. 20.
21. 22. 23. 24.
(II)
40
1. 32 (24hr+8hr) 2. 3. _8 4. _8 5. _ 8 6. _8 7. _8 8. _3 9. 1_2432 10.2_ 8
l ()
l //TFDA: 1000/ l : : 1200/ l : 600/
l l /TFDA: : 700/ l : : 2000/6 : 200//3
l l : : 100, 8/, , l TFDA: /: 200/ l / : 300/ 600 / l (): 300/
41
ü 42
l 22
l / AABB( )
43
l : (1) [ IC(//) ]
(2)// (3)//
l
l
l GDP lGPP ü
ü ü



 101  03   28  10  101 10  24       7  8  ( )
 ( )
 ( )
2  
3 6.,1 2,
4 2.
4 5. ,
 2+2+2+2/ 4x7 = 8/28 = 0.286  6+6+6+5/ 4x7 = 23/28 = 0.822
2. ()
:53.9±16.2 :44.8±18.2 - 17%
: 60.97±28.72 : 48.54±27.01 -20.39%

61,512±483 52,948±508 - 14% -$42,528,824
56,896±489 47,948±447 - 15.7%
-$71,924,024
-$63,255,767
-$66,366,180
14,377±16,961 14,024±69,969 -3%
: 13,993±21,136 : 12,483±19,147 -10.79%
  ( : )
5,098,000 12,660,552
= 1 : 2.5
32,255,000 24,441,274
= 1 : 0.8
34,012,000 42,528,824
= 1 : 1.3
49,302,000 71,924,024
= 1 : 1.5
51,362,000 63,255,767
= 1 : 1.2
41,273,340 66,366,180
= 1 : 1.6
3.–
U tility
Fig.4: EQ-5D-5L index values at second and sixth visit indicating enhancement of HRQoL. *p value < 0.001
. Mean:0.61 (SD:0.25)
0.78 (0.18)*
.55000
.60000
.65000
.70000
.75000
.80000
u 4.3(1~5) u1.4( - 2~+2) u 8.6( 0~10) u 4.2(1~5)
52
53

()
() / / () ()


/





/

l: l: //